News

Download the Complete Report Here Aurora Cannabis Inc. (ACB) Y26 Beat Underscores Medical Cannabis Momentum; FY27 Reset Reflects Canadian Reimbursement Cut, but Long-Term Growth Remains on Track. Key Takeaways: FY26 topped management’s outlook, with net revenue up 11% to C$320.6 million and medical cannabis revenue up 18%. 4Q revenue grew 10% y/y to C$84.8 million, […] The post Aurora Cannabis Generates 55% Revenue Outside Canada as Medical Sales Surge – Quarterly Update Report appeared first on

Investors seeking exposure to the marijuana market may now have a more attractive option to consider.

Key Takeaways; Cannabis Sector Aurora Cannabis Posted Record Medical Cannabis Revenue as International Growth Drove Fiscal 2026 Performance Trulieve Made History with NYSE Listing as CEO Sees New Era for U.S. Cannabis Tilray Medical Launched its First German-Grown Premium Cannabis Brand ARX Village Farms Expanded Dutch Production and Launched Pink Kush Vape in Canada Key […]

There are good things taking shape at Tilray, but there's one overriding theme that you can't ignore.

Trulieve's price has soared this year, while Tilray's has plummeted, but which is the better stock right now?

Tilray is launching 24 of its US craft beer SKUs through BrewDog's bars and website.

Tilray’s ARX brand will be launched at the world's largest cannabis expo and festival, Mary Jane Berlin 2026, which kicks off in two days.

Cannabis stocks continue to benefit from Schedule III optimism, with investors now watching a June 29 hearing on broader marijuana rescheduling.

Tilray Brands, Inc. (TLRY) closed at $5.03 in the latest trading session, marking a +1.82% move from the prior day.

Most of Tilray's sales come from Canada and the European Union.

Tilray bought Brewdog on the cheap, but there's a reason why it got such a good price.

Tilray Brands is back in focus as analysts reset their thinking on where the stock might be headed, with some firms cutting price targets in both US$ and C$ while others keep their fair value view anchored. Those target trims of about US$2 to US$3 per share and about C$3.50 are tied directly to mixed Street commentary that balances enthusiasm around cannabis rescheduling with caution on profitability and execution risks. Read on to see what these shifting targets could mean for you and how to...

Tilray stock was in focus after a recent government effort to reclassify Hemp and the upcoming DEA hearing about marijuana.

Tilray Brands Inc. (NASDAQ:TLRY) is one of the best sin stocks to buy now. On May 5, Tilray Brands Inc. (NASDAQ:TLRY) subsidiary BrewDog inked a 12-month partnership with Underbelly. The agreement is for the supply of beer at several UK festivals and venues. BrewDog is to become the official beer supplier at Christmas in Trafalgar […]

The latest trading day saw Tilray Brands, Inc. (TLRY) settling at $5.38, representing a -2% change from its previous close.

Tilray Brands Inc (NASDAQ:TLRY) is one of the best CBD stocks to buy right now. Although Tilray Brands Inc (NASDAQ:TLRY) stock is up only a modest 19% over the past year, analysts see the stock soaring more than 50% over the next 12 months. On May 26, Tilray Medical joined talks on medical cannabis regulations […]

Don't hold your breath.

Tilray stock reaction to U.S. policy news and new Carlsberg partnership Tilray Brands (TLRY) is back in focus after U.S. cannabis reclassification headlines, a fresh multi-year partnership with Carlsberg, and a recent share price decline even as many cannabis peers gained. See our latest analysis for Tilray Brands. Despite the policy headlines and new Carlsberg partnership, Tilray’s share price has fallen 32.78% over the past month and 45.58% year to date, while the 1 year total shareholder...

Tilray Brands’ fair value estimate currently stands at $10.04, with the latest update keeping this price target unchanged. Even with several analysts trimming their targets in both US$ and C$, others are turning more constructive after the partial cannabis rescheduling order and the BrewDog asset acquisition. As you read on, you will see how these competing views shape the evolving story around Tilray and what to watch as the narrative shifts. Analyst Price Targets don't always capture the...

Tilray's business has gotten bigger over the years, but it continues to struggle with achieving profitability.

International growth could make up for a lack of U.S. legalization progress

Recently, Zacks.com users have been paying close attention to Tilray Brands (TLRY). This makes it worthwhile to examine what the stock has in store.

Or is it just a value trap?

SNDL faces pressure after Q1 results show falling sales, weak cannabis demand, and margin strain, raising concerns about growth in a saturated Canadian market.

Most regulatory headwinds remain for cannabis companies like Tilray.

Marijuana rescheduling may have taken place in the U.S., but that doesn't mean legalization will happen anytime soon.

Tilray Brands, Inc. (NASDAQ:TLRY) is one of the 7 Best Hemp Stocks To Buy Now. On April 22, Bloomberg reported, citing an on-air discussion with CEO Irwin Simon, that Tilray Brands, Inc. (NASDAQ:TLRY) shares rose by around 10% after surging as much as 18% earlier, amid strong trading activity of more than 20 million shares. […]

Tilray doesn't fit squarely into the value trap or value stock categories.

Tilray Brands (TLRY) surged in premarket trading on fresh enthusiasm over marijuana rescheduling, then gave back much of the move as the session unfolded. The early excitement followed a U.S. government shift to reclassify certain marijuana products and a market rush into cannabis names. By later ...

The Trump administration also announced the beginning of an expedited administrative hearing process to consider the rescheduling marijuana more broadly.